The selective mu opioid receptor antagonist, alvimopan, improves delayed GI transit of postoperative ileus in rats

Area of Science:

• Pharmacology
• Gastroenterology
• Surgical Research

Background:

• Postoperative ileus (POI) is a common complication following abdominal surgery.
• Opioid analgesics, commonly used for pain management, can exacerbate POI by delaying gastrointestinal (GI) transit via mu opioid receptor activation.
• Peripherally acting mu opioid receptor antagonists offer a potential therapeutic strategy for mitigating opioid-induced GI dysfunction.

Purpose of the Study:

• To investigate the efficacy of alvimopan, a selective peripherally acting mu opioid receptor antagonist, in a rat model of postoperative ileus.
• To compare the effects of alvimopan with methylnaltrexone, another mu opioid receptor antagonist, on GI transit following surgery.
• To evaluate the impact of timing of alvimopan administration (pre- vs. post-surgery) and its interaction with morphine on POI.

Main Methods:

• Postoperative ileus was induced in rats via laparotomy and intestinal manipulation under isoflurane anesthesia.
• GI transit was assessed using the geometric center (GC) of orally administered chromium-51 ((51)Cr).
• Rats received varying doses of alvimopan or methylnaltrexone, with or without morphine, administered before or after surgery.

Main Results:

• Surgical manipulation significantly delayed GI transit (GC = 2.92 ± 0.17).
• Alvimopan (1 and 3 mg/kg) administered pre-surgery significantly reversed the delayed GI transit.
• Morphine further exacerbated the ileus, but alvimopan still showed efficacy when given pre-surgery.
• Methylnaltrexone (100 mg/kg) did not demonstrate significant effects on GI transit under any tested conditions.
• The efficacy of alvimopan was reduced when administered post-surgery compared to pre-surgery.

Conclusions:

• Mu opioid receptors play a significant role in the pathophysiology of postoperative ileus.
• Alvimopan demonstrates efficacy in reversing experimental POI, potentially through blocking endogenous opioid effects and counteracting exogenous opioid-induced GI stasis.
• The timing of alvimopan administration is critical, with pre-surgical treatment yielding more pronounced benefits.
• Methylnaltrexone was found to be ineffective in this model, suggesting differential mechanisms or receptor interactions.
• These findings support the potential clinical utility of alvimopan in managing POI, possibly by inhibiting endogenous opioid release and mitigating analgesic side effects.